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Throughout the literature, enzyme constants have been derived by utilizing in vivo data and in- 
directly assuming that these data were described by the one-compartment open model. However, 
many drugs are probably best described by a two-compartment open model with Michaelis-Menten 
elimination kinetics. Simulated data, which obey the two-compartment open model with Michaelis- 
Menten elimination, and which illustrate some of the interesting properties of such models, are 
presented Treatment of two-compartment data by one-compartment analysis is shown to result 
in a serious distortion of enzyme parameters ( V,,, Kin). For data which obey the two-compartment 
open model, estimation of the Michaelis-Menten constant (Kin) and the maximum velocity ( Vm) 
by one-compartment analysis cannot be theoretically justified and therefore should be avoided. 
KEY W O R D S :  Michaelis Menten kinetics; dose-dependent kinetics; one-compartment 
model; two-compartment model. 
INTRODUCTION 
The classical linear pharmacokinetic models have been successfully 
used to accurately describe rates of absorption, metabolism., and excretion 
when applied to certain specific drugs and have been very useful for pre- 
dictive purposes. During the past decade, many reports have provided 
evidence that linear systems of differential equations do not accurately 
describe the pharmacokinetic behavior of many compounds. Nonlinear 
pharmacokinetics to date are based on the Michaelis-Menten and Langmuir 
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tissue-binding equations. Several authors (1-4) have successfully used 
nonlinear pharmacokinetic models involving Michaelis-Menten equations 
to describe drug concentration-time data. However, these authors obtained 
val'aes for the constants, V,, and Kin, either from separate experiments 
(e.g., from in vitro studies) or by fitting data directly to the one-compartment 
open model with Michaelis-Menten elimination. Many of the methods 
used to indirectly evaluate enzyme constants in animals cannot be used in 
human beings. In addition, other authors (5-6) have shown that in vitro 
enzyme constants are markedly dependent on experimental conditions. 
This sensitivity can introduce a large amount of uncertainty into the values 
of enzyme constants obtained from in vitro studies because in vitro enzyme 
environment may not accurately simulate conditions existing in vivo. 
Direct pharmacokinetic estimation of enzyme constants avoids the 
problems above, but, as will be demonstrated, correct evaluation of these 
constants requires the use of an appropriate pharmacokinetic model. 
Dedrick and Forrester (7) discussed the errors introduced into the 
values of V,, and Km when data described by a special form of, the two- 
compartment model were analyzed according to the one-compartment 
open model. 
Wagner and  Patel (3) used the one-compartment open model to 
analyze enzyme constants describing ethanol metabolism in man. Their 
data indicate the presence of a distribution phase, which is particularly 
evident after the administration of 60 ml of 95% ethanol. This suggests 
that a two-compartment model involving Michaelis-Menten elimination 
may prove to be a more accurate representation of pharmacokinetics of 
ethanol in man, and the remarks made by Dedrick and Forrester may 
apply. Therefore, the recognition of data described by multicompartment 
models and the consequences of analyzing such data by use of the one- 
compartment model are of considerable interest and importance. 
The purposes of this paper are: 
1. To discuss some of the properties of the two-compartment open 
model with Michaelis-Menten elimination. 
2. To demonstrate the effects of fitting data which were generated 
with the equations of a two-compartment model involving 
Michaelis-Menten elimination kinetics by using the equations 
of a one-compartment model with Michaelis-Menten elimination 
kinetics. 
T H E O R Y  
A two-compartment open model involving first-order absorption 
and Michaelis Menten elimination from the central compartment is shown 
schematically in scheme 1 : 
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compartment 2 I 
k~ ] Kzl 
k~ ] V. 
, compartment 1 K~ 
The model can be described mathematically by the following differential 
equations: 
( Vm )C1+k21C 2 (1) dCldt = kaC~176 - k12 + K,. + C1 
dC2 
= k12 C1 - k21C2 (2) dt 
where Co is the dOse of drug/volume of compartment 1 (mg/mI), C1 is the 
concentration of drug in compartment 1 (mg/ml), Cz is the amount of drug 
in compartment 2/volume of compartment 1 (mg/ml), t is time (hr), ka is the 
first-order absorption rate constant (hr- ~), kaz is the first-order distribution 
rate constant from compartment 1 to compartment 2 (hr-a), k21 is the 
first-order distribution rate constant from compartment 2 to compartment 1 
(hr-1), V,, is the maximum reaction rate [mg/(ml)(hr)], and K,, is the 
Michaelis constant (mg/ml). 
A one-compartment model with Michaelis-Menten elimination is 
shown in scheme 2: 
V~ compartment 1 K~ ' 
The model is mathematically described by 
dCa _ V,, " Ca (3) 
dt Km+ Ca 
where the symbols are defined as above. 
These equations can be used to obtain values of C~ and/or Cz as a 
function of time by numerical integration. They also may be used in a 
similar manner to fit drug concentration-time data by means of a nonlinear 
least-squares estimation program and a high-speed digital computer. 
E X P E R I M E N T A L  
Generation of  Simulated C,t  Data  
Simulated C,t data obeying equations 1 and 2 were generated by 
assigning numerical values to Co, k,, k12, k21, Vm, and Km using the program 
NONLIN and an IBM 360/67 computer. Equations 1 and 2 were numerically 
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integrated by the computer using the Runge-Kutta method, which is a 
part of the program NONLIN. The simulations were performed with 
Vm = 0.418; Km= 0.182; k12 = 3; k21 = 2; k , =  8, 4, 2, 1, and 0.5; Co = 3, 
2, and 0.5. 
Fitting of Simulated C,t Data 
The terminal portions of all of the sets of simulated data were fitted 
to the one-component open model with Michaelis-Menten elimination 
kinetics (scheme 2) by utilizing a linear transformation of equation 3. This 
technique is discussed in the Appendix. The constants for one set of data 
(ka = 8 and Co = 2) were also evaluated by two additional means: (a) a 
Lineweaver-Burk plot (8) of the terminal data and (b) nonlinear least- 
squares computer fitting of the terminal data to equation 3. 
RESULTS AND DISCUSSION 
Some of the C,t data generated as described in the Experimental 
section are plotted on cartesian coordinate graphs in Figs. 1 and 2. These 
curves are characterized by an early distribution phase (a "nose" evident at 
the higher doses) followed by a pseudolinear region, then terminating in a 
curved portion. The presence of the distribution phase, indicated by the 
steeper slope of the blood concentration curve just past the peak, becomes 
increasingly apparent as the absorption rate and/or the dose of drug are 
raised. The slope of the subsequent pseudolinear phase (ko) is markedly 
dependent on both the absorption rate and the dose of drug (Fig. 3). The 
magnitude of ko is only a small percentage of the maximum velocity, Vm, 
and therefore does not represent the maximum metabolic rate of the drug. 
The value of this slope, alone, cannot be used to estimate any of the enzyme 
parameters. As illustrated by Figs. 4 and 5, the peak drug concentration and 
the areas under the C,t curves (0-6 hr) are both dependent on the rate of drug 
absorption and the dose of drug. Although not shown, the relationships 
of total area (0-oe hr) under the C,t curves to Co and/ca are very similar 
to those shown in Fig. 5. Slowing the absorption rate of a drug which is 
fully absorbed not only decreases the peak drug concentration but also 
decreases the area under the C,t curve. These phenomena would also be 
predicted by the one-compartment open model with first-order absorption 
and Michaelis-Menten elimination, but could not be explained by the 
classical linear one- or two-compartment open models. Either nonlinear 
model could help explain the effects of food and stomach emptying on drug 
blood levels and bioavailability. Even for drugs which are fully absorbed, 
these models would predict decreases in drug blood concentration and 
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Fig.  1. Effect  o f  d r u g  a b s o r p t i o n  r a t e  o n  s i m u l a t e d  c o n c e n t r a t i o n  d a t a  when  d a t a  were  
g e n e r a t e d  f r o m  the  t w o - c o m p a r t m e n t  o p e n  m o d e l  ( scheme 1) wi th  k12 = 3, k2~ = 2, 
Vm = 0 .418,  a n d  K,, = 0.182.  
bioavailability when food was administered or s tomach emptying was 
slowed because of a decreased rate of  drug absorption. 
The values listed in Table I demonstrate  the effect of  using the one- 
compar tment  open model (scheme 2) to fit data which were generated using 
the two-compar tment  open model (scheme 1). In order to compare  the 
procedure outlined in the Appendix with more commonly  used methods, 
the enzyme constants for one set of  data (ka = 8, Co = 2) were also analyzed 
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Fig. 2. Effect of  change in dose (Co value) on simulated concentration data when 
data were generated from the two-compartment  open model (scheme 1) with k12 = 3, 
k2~ = 2 ,  V,, = 0.418, K,, = 0.182, and ka = 4. 
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the simulated blood concentration curve. 
by constructing a Lineweaver-Burk plot (8) from the terminal data (Fig. 6) 
and by nonlinear least-squares computer fitting of the terminal data to the 
Michaelis-Menten equation (equation 3). The former method yielded values 
of / / ' , ,=0.180 and K,  = 0.238. Values of V,, = 0.176 and Km= 0.227 were 
obtained from the computer fitting. Both sets of estimates agree reasonably 
well with those listed in Table I. As illustrated in Table I, the following are 
observed when two-compartment data are fitted to a one-compartment 
model: (a) Enzyme constants estimated in such a manner bear little relation- 
ship to the values of the kinetic constants used in the simulations. Moreover, 
the estimated values of  the constants are dependent on the drug absorption 
rate (ka) and the dose of drug. (b) The value of V,,/K,, estimated by use of 
the one-compartment open model is always much less than the value used 
to generate the two-compartment open model data. It is not surprising that 
the values of V,,/K,, obtained by the fitting of  simulated data to the one- 
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Table I. Vm and K,, Values Estimated from Terminal  Simulated Concentrat ion 
Data  According to One-Compar tment  Open Model (scheme 2) Analysis When 
Data Were Generated from the Two-Compar tmen t  Open Model (scheme 1) with 
kl2 = 3, k2l = 2, V~ = 0.418, and K,~ = 0.182 
One-compar tment  model estimates 
Co k, Time interval ~ 
(mg/ml) (hr l) (hr) Vm gm 
3 8 3.6-9.6 0.174 0.223 
3 4 3.6-9.6 0.174 0.223 
3 2 3.6-9.6 0.174 0.223 
3 1 4.5-10.0 0.163 0.200 
3 0.5 6.5-10.5 0.134 0.162 
2 8 1.8 8.3 0.179 0.239 
2 4 1.8 8.3 0.184 0.248 
2 2 1.8-8.3 0.177 0.233 
2 l 3.0-8.5 0.139 0.165 
2 0.5 5.0-10.0 0.t13 0.161 
0.5 8 1 .6~.3  0.240 0.341 
0.5 4 t .9~,.3 0.275 0.395 
0.5 2 1.9~4.6 0.232 0.329 
0.5 l 2 . 44 .8  0.069 0.093 
0.5 0.5 3.0-7.0 0.028 0.047 
"Blood concentrat ions during this time interval were used to estimate Vm and Km 
using a linear t ransformat ion of the Michaelis Menten equation (see Appendix). 
compartment open model are fairly close to the value of 13, 3 the apparent 
elimination rate constant of the two-compartment open model. (c) The 
value of Vm estimated by one-compartment analysis is always less than the 
Vm of the two-compartment open model. (d) The value of Km may be ap- 
preciably overestimated or underestimated when two-compartment data 
are analyzed by the use of a one-compartment open model. 
Nonlinear in vivo data have in the past almost exclusively been analyzed 
using one-compartment analysis. The above simulations illustrate that 
one-compartment analysis of real data, which "actually" obey the two- 
compartment model, would yield numbers having very little relationship 
to those which would be obtained by two-compartment analysis. In vitro 
enzyme constants are often determined by incubating purified enzyme with 
substrate in a well-stirred system. Such an in vitro system would be expected 
to obey the one-compartment open model. Thus enzyme parameters 
determined from in vitro experiments, by utilizing one-compartment analysis 
(e.g., Lineweaver-Burk plots), should accurately reflect the in vitro enzyme 
constants under the particular experimental conditions. Moreover, if 
3fl = 1/2{(k12 + k21 + Vm/Km ) _ [(k~ 2 + k2 ~ + Vm/K,.)2 _ 4- k21  " Vrn/K~]l/2}. For the ex- 
amples in the text, fl = 0.700. 
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in vitro experimental conditions accurately simulated in vivo enzyme environ- 
ment, the values of these in vitro constants would be the same as the in vivo 
values. For drugs described by the two-compartment open model, in vivo 
enzyme constants obtained by one-compartment analysis do not agree 
well with the "true" values used in the simulations. Therefore, for these 
drugs, in vivo enzyme constants obtained by one-compartment analysis 
would not be expected to agree with values obtained in vitro. If there is 
agreement between in vivo and in vitro enzyme constants (both based on 
the one-compartment open model), it is feasible that this may be explained 
by the fact that either the one-compartment open model does adequately 
explain the in vivo data or the in vivo data are describable by a multicompart- 
ment model and the in vitro experimental conditions were fortuitously 
chosen in such a manner that agreement was obtained. .  
Decreases in relative bioavailability (based on area under blood C,t 
curves) are often observed when drugs are administered at different doses 
and/or concomitantly with food. Classical pharmacokinetic models cannot 
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easily explain these decreases for drugs which are fully absorbed. The one- 
and two-compartment open models with Michaelis-Menten elimination 
kinetics predict decreases in relative area under blood C,t curves when 
smaller doses of drugs are administered or if the rate of drug absorption 
is slowed. The latter model may prove to be of value for describing the 
effect of food, etc., on bioavailability for drugs which distribute into a 
second compartment. 
CONCLUSION 
Values of apparent enzyme constants, V,, and K,,, estimated by utilizing 
one-compartment analysis for drugs which are actually described by the 
two-compartment open model involving Michaelis-Menten elimination 
kinetics bear little relationship to the values of these constants applicable 
to the multicompartmental system. To distinguish a one-compartment 
from a multicompartmental system, the simulations discussed have indicated 
that blood levels need be measured after several different doses of a drug. 
At low doses there may be no "nose" on the blood concentration profile, 
whereas at higher doses the "nose" becomes prominent (see Figs. 1 and 2). 
Once such a "nose" is seen, the investigator should become aware that the 
appropriate model most probably is a multicompartmental one. It is this 
"nose," evident in the alcohol data reported by Wagner and Patel (3), 
which leads the authors to believe that pharmacokinetics of ethanol in man 
involves a multicompartmental rather than a one-compartment model. 
This is being pursued with intravenous studies in man and will be reported 
at a later date. 
APPENDIX 
Calculation of the Values of V,. and Km Utilizing the One-Compartment 
Open Model and Terminal Data Obtained from Computer Simulations 
of the Two-Compartment Model with Michaelis-Menten Elimination 
Kinetics 
The one-compartment model (scheme 2) is described mathematically by 
dC V,,, C 
dt K m + C (A1)  
If one assumes AC/At ~_ dC/dt, this equation can be rearranged to give 
C r~ 1~. m 1 
-AC/At  =-V-2. + C (a2) 
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A Woolf  plot (8) is a plot of  C / -  (AC/At) vs. C, where C is the average 
concentration of  drug during the time interval (At). This gives a straight 
line having a slope of 1/Vm and an intercept of  K,,/V~. 
The following leads to a modification of the Woolf  plot: 
which rearranges to 
1 dC d In C 




-dC/dt - d l n  C 
Thus for two points, n and n + 1, 
C At 
-AC/At  - A l n  C 
t,+ 1 - t. (A5) 
In C. - In C. + 1 
Instead of using the arithmetic midpoint  of  6". and C,+1 as the cor- 
responding value of C, it is probably better to use the geometric mean of 
6", and C.+ 1. 
Hence for points n and n + 1, 
C : (Cn"  C n + l )  1/z = e (Inc"+lnc"+l)/2 (A6) 
Substituting equations 5 and 6 into equation 2 gives 
= 1 t , + l - t ,  K,, + .(Cn. Cn+l)l/2 
In C . - l n  C,+I  Vm 
(y) (x) 
Values of  y and x were obtained by using simulated C,t data. Linear 
regression of y on x gave an apparent  straight line whose slope was 1IV. 
and intercept was Km/V,~. These were solved to obtain estimates of  Vm 
and K,,. 
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